We are live on
!
Find out more
TI
tru Independence Portfolio holdings
AUM
$229M
1-Year Est. Return
22.02%
This Fund
S&P 500
This Quarter
Est. Return
-20.27%
1 Year Est. Return
+22.02%
3 Year Est. Return
+55.73%
5 Year Est. Return
+56.97%
10 Year Est. Return
–
AUM
$613M
AUM Growth
-$81.7M
(-12%)
Cap. Flow
-$229M
Cap. Flow
% of AUM
-37.38%
Top 10 Holdings %
Top 10 Hldgs %
43.1%
Holding
965
New
6
Increased
47
Reduced
75
Closed
214
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$23.5M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$22.6M |
| 3 |
iShares Core S&P US Value ETF
IUSV
|
+$18.8M |
| 4 |
Schwab International Equity ETF
SCHF
|
+$14.3M |
| 5 |
First Trust NYSE Arca Biotechnology Index Fund
FBT
|
+$14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$49.3M |
| 2 |
DTE Energy
DTE
|
+$17M |
| 3 |
Starbucks
SBUX
|
+$9.35M |
| 4 |
Brighthouse Financial
BHF
|
+$8.94M |
| 5 |
BNY
Bank of New York Mellon
BNY
|
+$8.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 44.3% |
| 2 | Technology | 10.3% |
| 3 | Healthcare | 9.04% |
| 4 | Financials | 7.78% |
| 5 | Consumer Staples | 6.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Columbia Emerging Markets Consumer ETF
ECON
$320M
| $74M | 12.06% |
195
| – | – |
|
|
BMY.RT
2
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $49.3M | 8.03% |
1,081,698
+1,081,643
| +1,966,624% | +$3.56M |
|
|
3
iShares Core S&P US Value ETF
IUSV
$28B
| $29.8M | 4.85% |
329,917
+327,380
| +12,904% | +$18.8M |
|
|
4
Schwab International Equity ETF
SCHF
$69.8B
| $24.1M | 3.93% |
1,153,408
+931,920
| +421% | +$14.3M |
|
|
5
State Street SPDR S&P Biotech ETF
XBI
$11.7B
| $21.5M | 3.5% |
378,743
+265,559
| +235% | +$23.5M |
|
|
6
State Street Energy Select Sector SPDR ETF
XLE
$42.1B
| $21M | 3.42% |
1,236,696
+954,894
| +339% | +$22.6M |
|
7
Cognizant
CTSH
$29.1B
| $16M | 2.6% |
225
-600
| -73% | -$35.8K |
|
8
Gilead Sciences
GILD
$188B
| $10.1M | 1.65% |
135,656
| – | – |
|
9
Microsoft
MSFT
$3.79T
| $10.1M | 1.65% |
64,271
-26,180
| -29% | -$4.31M |
|
10
Coca-Cola
KO
$382B
| $8.54M | 1.39% |
6,116
-2,423
| -28% | -$131K |
|
11
Citigroup
C
$232B
| $8.2M | 1.34% |
3,247
-4,951
| -60% | -$332K |
|
12
Apple
AAPL
$4.79T
| $7.7M | 1.26% |
121,136
-66,700
| -36% | -$4.91M |
|
13
CVS Health
CVS
$124B
| $7.29M | 1.19% |
122,858
-4,105
| -3% | -$274K |
|
14
Pfizer
PFE
$164B
| $6.99M | 1.14% |
225,778
-126,454
| -36% | -$4.31M |
|
15
Intel
INTC
$485B
| $6.58M | 1.07% |
121,513
-83,102
| -41% | -$4.92M |
|
16
Vanguard Industrials ETF
VIS
$7.96B
| $5.91M | 0.96% |
47,292
+37,534
| +385% | +$5.32M |
|
17
AT&T
T
$179B
| $5.69M | 0.93% |
258,504
-241,975
| -48% | -$6.61M |
|
|
18
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.98B
| $5.63M | 0.92% |
98,614
+98,267
| +28,319% | +$14M |
|
19
JPMorgan Chase
JPM
$962B
| $5.57M | 0.91% |
61,844
-45,088
| -42% | -$5.48M |
|
20
Vanguard Short-Term Bond ETF
BSV
$45.4B
| $5.44M | 0.89% |
63,728
+28,550
| +81% | +$2.32M |
|
21
PIMCO Investment Grade Corporate Bond Index Exchange-Traded Fund
CORP
$1.45B
| $5.42M | 0.88% |
51,222
+6
| +0% | +$657 |
|
22
Bank of America
BAC
$441B
| $5.32M | 0.87% |
250,474
-15,225
| -6% | -$456K |
|
23
Merck
MRK
$376B
| $4.9M | 0.8% |
35,336
-54,077
| -60% | -$4.25M |
|
24
General Mills
GIS
$21B
| $4.74M | 0.77% |
89,745
-84,225
| -48% | -$4.45M |
|
25
Kroger
KR
$35.8B
| $4.71M | 0.77% |
156,358
-256,430
| -62% | -$7.53M |
|
Similar funds
IAAG
AAG
WCM
PPA
DCC
SWIM
PRRFG
CAIM
tru Independence's Q1 2020 Portfolio in Review
As of Q1 2020, tru Independence held 965 positions worth $613M, down 12% from $695M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
tru Independence withdrew a net $229M in Q1 2020, closing 214 positions and reducing 75 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $49.3M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, up from 21% a quarter earlier, followed by Technology and Healthcare.
Against the trend, tru Independence opened a new position in Norbord Inc. worth $3.02M.
- tru Independence's largest Q1 2020 buy was Norbord Inc.: 254,795 shares worth $3.02M.
- tru Independence added most to State Street SPDR S&P Biotech ETF in Q1 2020, an estimated $23.5M increase.
- tru Independence's biggest Q1 2020 reduction was DTE Energy, cutting an estimated $17M.
- tru Independence fully exited Bristol-Myers Squibb in Q1 2020, selling an estimated $49.3M.
- tru Independence's ten largest holdings make up 43% of its $613M portfolio in Q1 2020.
- tru Independence opened 6 new positions and closed 214 in Q1 2020.
- tru Independence's portfolio value fell 12% quarter-over-quarter to $613M.
Based on tru Independence's 13F filing for Q1 2020, filed 19 May 2020.